Patents by Inventor Gregg F. Keaney

Gregg F. Keaney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potassium channel modulators
    Patent number: 10351553
    Abstract: Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 16, 2019
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20190100513
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: November 17, 2016
    Publication date: April 4, 2019
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20180215746
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • METHODS FOR THE TREATMENT OF TREMORS BY POSITIVE MODULATION OF SK CHANNELS
    Publication number: 20180207138
    Abstract: Provided herein is the use of one or more small-conductance calcium-activated potassium channel positive modulators (SK positive modulators) for the treatment of tremors.
    Type: Application
    Filed: January 23, 2018
    Publication date: July 26, 2018
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Martin R. Jefson, Gregg F. Keaney, Karin Sandager Nielsen
  • Potassium channel modulators
    Patent number: 9975886
    Abstract: Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 22, 2018
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • Enzymatic transamination of cyclopamine analogs
    Patent number: 9879293
    Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 30, 2018
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20170355708
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: June 8, 2017
    Publication date: December 14, 2017
    Inventors: Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall
  • TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20170119734
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof, wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 4, 2017
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Pladienolide pyridine compounds and methods of use
    Patent number: 9481669
    Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 1, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim
  • ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
    Publication number: 20160177354
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 23, 2016
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • Tetrazolones as inhibitors of fatty acid synthase
    Patent number: 9346769
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 24, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Pladienolide Pyridine Compounds and Methods of Use
    Publication number: 20150329528
    Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 19, 2015
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai
  • Enzymatic Transamination of Cyclopamine Analogs
    Publication number: 20140371456
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: April 21, 2014
    Publication date: December 18, 2014
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • Enzymatic transamination of cyclopamine analogs
    Patent number: 8703448
    Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 22, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20140079667
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 20, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8609706
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 17, 2013
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Tetrazolones as inhibitors of fatty acid synthase
    Patent number: 8546432
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: October 1, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20130243727
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: April 29, 2013
    Publication date: September 19, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Adilah BAHADOOR, Alfredo C. CASTRO, Lawrence K. CHAN, Gregg F. KEANEY, Marta NEVALAINEN, Vesa NEVALAINEN, Stephane PELUSO, Thomas T. TIBBITTS
  • Triazoles as inhibitors of fatty acid synthase
    Patent number: 8450350
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 28, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20130131063
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: May 23, 2013
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts